XtalPi and Signet Expand AI Drug Discovery Collaboration to Novel Cancer Target

Signet Therapeutics and XtalPi Inc. announced the expansion of their AI drug discovery collaboration to include a new first-in-class program against a novel cancer target identified by Signet. The follow-on project will continue to combine XtalPi’s AI drug discovery platform with Signet’s unique novel organoid disease models to generate pipeline candidates and advance them toward clinical trials.